Top

Published in:

01-08-2018 | Review

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University

Authors: Nikolaus Marx, Heidi Noels, Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm

Published in: Clinical Research in Cardiology | Special Issue 2/2018

Abstract

Patients with chronic kidney disease (CKD) exhibit a massively increased risk for cardiovascular (CV) events, and traditional strategies to improve CV outcome have largely failed in the context of CKD. This review article summarizes the current understanding of the pathophysiology of CVD in patients with CKD, defines the gaps in knowledge and describes the structure of the German Transregional Research Consortium SFB TRR219 which addresses “Mechanisms of Cardiovascular Complications in Chronic Kidney Disease”.

Stevens PE, O’Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK (2007) Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 72(1):92–99. https://doi.org/10.1038/sj.ki.5002273 CrossRefPubMed

Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M (2015) Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol 26(10):2504–2511CrossRefPubMedPubMedCentral

Drey N, Roderick P, Mullee M, Rogerson M (2003) A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 42(4):677–684CrossRefPubMed

Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O’Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC (2015) US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 65(6 Suppl 1):A7CrossRef

Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML (2001) Uremic toxicity: present state of the art. Int J Artif Organs 24(10):695–725CrossRefPubMed

Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383(9931):1831–1843CrossRefPubMed

Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380(9844):807–814CrossRefPubMed

El Nahas AM, Bello AK (2005) Chronic kidney disease: the global challenge. Lancet 365(9456):331–340. https://doi.org/10.1016/S0140-6736(05)17789-7 CrossRef

Hippisley-Cox J, Coupland C (2010) Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 11:49. https://doi.org/10.1186/1471-2296-11-49 CrossRefPubMedPubMedCentral

10.

Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, Levin A (2013) Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382(9887):158–169. https://doi.org/10.1016/S0140-6736(13)60439-0 CrossRefPubMed

11.

Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transpl 20(6):1048–1056CrossRef

12.

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17(7):2034–2047CrossRefPubMed

13.

Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106(14):1777–1782CrossRefPubMed

14.

Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351(13):1285–1295. https://doi.org/10.1056/NEJMoa041365 CrossRefPubMed

15.

Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E (2004) Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 25(22):1998–2005CrossRefPubMed

16.

Shamseddin MK, Parfrey PS (2011) Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 7(3):145–154. https://doi.org/10.1038/nrneph.2010.191 CrossRefPubMed

17.

Cotter G, Davison BA, Butler J, Collins SP, Ezekowitz JA, Felker GM, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Senger S, Bharucha D, Goin K, Soergel DG, Pang PS (2018) Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clin Res Cardiol 107(2):170–181. https://doi.org/10.1007/s00392-017-1168-0 CrossRefPubMed

18.

Bistola V, Simitsis P, Farmakis D, Ikonomidis I, Bakosis G, Triposkiadis F, Hatziagelaki E, Lekakis J, Mebazaa A, Parissis J (2018) Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol 107(1):76–86. https://doi.org/10.1007/s00392-017-1161-7 CrossRefPubMed

19.

Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, Bakosis G, Hatziagelaki E, Lekakis J, Mebazaa A, Parissis J (2017) Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 106(5):359–368. https://doi.org/10.1007/s00392-016-1063-0 CrossRefPubMed

20.

Fleischmann EH, Bower JD, Salahudeen AK (2001) Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol 56(3):221–230PubMed

21.

Iseki K, Fukiyama K (2000) Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 36(4):820–825CrossRefPubMed

22.

Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD (2003) Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63(3):793–808CrossRefPubMed

23.

Schlieper G, Hess K, Floege J, Marx N (2016) The vulnerable patient with chronic kidney disease. Nephrol Dial Transplant 31(3):382–390CrossRefPubMed

24.

Emrich IE, Zawada AM, Martens-Lobenhoffer J, Fliser D, Wagenpfeil S, Heine GH, Bode-Boger SM (2018) Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin Res Cardiol 107(3):201–213. https://doi.org/10.1007/s00392-017-1172-4 CrossRefPubMed

25.

McCullough PA (2003) Why is chronic kidney disease the “spoiler” for cardiovascular outcomes? J Am Coll Cardiol 41(5):725–728CrossRefPubMed

26.

Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99(18):2434–2439CrossRefPubMed

27.

Gelev S, Spasovski G, Dzikova S, Trajkovski Z, Damjanovski G, Amitov V, Sikole A (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40(3):763–770CrossRefPubMed

28.

Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20(7):1453–1464CrossRefPubMed

29.

Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K (2000) Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transpl 15(2):218–223CrossRef

30.

Perl J, Chan CT (2006) Timing of sudden death relative to the hemodialysis procedure. Nat Clin Pract Nephrol 2(12):668–669. https://doi.org/10.1038/ncpneph0345 CrossRefPubMed

31.

Bleyer AJ, Russell GB, Satko SG (1999) Sudden and cardiac death rates in hemodialysis patients. Kidney Int 55(4):1553–1559. https://doi.org/10.1046/j.1523-1755.1999.00391.x CrossRefPubMed

32.

Foley RN, Gilbertson DT, Murray T, Collins AJ (2011) Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 365(12):1099–1107. https://doi.org/10.1056/NEJMoa1103313 CrossRefPubMed

33.

Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ, Ishihara S, AlHabib KF, Maggioni A, Miro O, Sato N, Cohen-Solal A, Fairman E, Lassus J, Harjola VP, Mueller C, Peacock FW, Choi DJ, Plaisance P, Spinar J, Kosiborod M, Mebazaa A, Gayat E (2018) Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol 107(3):214–221. https://doi.org/10.1007/s00392-017-1173-3 CrossRefPubMed

34.

Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17(11):1410–1422CrossRefPubMed

35.

Koleganova N, Piecha G, Ritz E, Schirmacher P, Muller A, Meyer HP, Gross ML (2009) Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transpl 24(8):2488–2496CrossRef

36.

Yoshida H, Yokoyama K, Yaginuma T, Ohkido I, Yamamoto H, Utsunomiya Y, Kawakami M, Hosoya T (2011) Difference in coronary artery intima and media calcification in autopsied patients with chronic kidney disease. Clin Nephrol 75(1):1–7PubMed

37.

Leskinen Y, Lehtimaki T, Loimaala A, Lautamatti V, Kallio T, Huhtala H, Salenius JP, Saha H (2003) Carotid atherosclerosis in chronic renal failure—the central role of increased plaque burden. Atherosclerosis 171(2):295–302CrossRefPubMed

38.

Nakano T, Ninomiya T, Sumiyoshi S, Onimaru M, Fujii H, Itabe H, Nakashima Y, Sueishi K, Tsuruya K, Oda Y, Kitazono T, Kiyohara Y (2013) Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama study. Kidney Int 84(2):373–380CrossRefPubMed

39.

Ketteler M, Rothe H, Kruger T, Biggar PH, Schlieper G (2011) Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7(9):509–516CrossRefPubMed

40.

Massy ZA, Maziere C, Kamel S, Brazier M, Choukroun G, Tribouilloy C, Slama M, Andrejak M, Maziere JC (2005) Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 20(3):380–382CrossRefPubMed

41.

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A (2012) Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23(7):1258–1270. https://doi.org/10.1681/ASN.2011121175 CrossRefPubMedPubMedCentral

42.

Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15(12):2959–2964. https://doi.org/10.1097/01.ASN.0000145894.57533.C4 CrossRefPubMed

43.

London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl 18(9):1731–1740CrossRef

44.

Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J (2013) Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transpl. https://doi.org/10.1093/ndt/gft459 CrossRef

45.

Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, Gamlen T, Ariens RA, Grant PJ, Ajjan RA (2012) Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97(12):E2282-2287. https://doi.org/10.1210/jc.2012-2128 CrossRef

46.

Hess K, Ajjan R, Phoenix F, Dobo J, Gal P, Schroeder V (2012) Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One 7(4):e35690. https://doi.org/10.1371/journal.pone.0035690 CrossRefPubMedPubMedCentral

47.

Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Luscher TF, Tanner FC (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35(43):3021–3032. https://doi.org/10.1093/eurheartj/ehu111 CrossRefPubMed

48.

Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58(1):353–362CrossRefPubMed

49.

Vanholder R, De Smet R (1999) Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10(8):1815–1823PubMed

50.

Shanahan CM (2013) Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol 9(11):661–670CrossRefPubMed

51.

Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M (2003) Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 112(2):256–264. https://doi.org/10.1172/JCI15524 CrossRefPubMedPubMedCentral

52.

Yu M, Kim YJ, Kang DH (2011) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6(1):30–39CrossRefPubMedPubMedCentral

53.

Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P (2005) Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 16(4):959–965. https://doi.org/10.1681/asn.2004070582 CrossRefPubMed

54.

Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71(4):549–574. https://doi.org/10.1007/s00018-013-1349-6 CrossRefPubMed

55.

McIntyre CW (2010) Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purif 29(2):105–110. https://doi.org/10.1159/000245634 CrossRefPubMed

56.

Burton JO, Jefferies HJ, Selby NM, McIntyre CW (2009) Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4(5):914–920. https://doi.org/10.2215/CJN.03900808 CrossRefPubMedPubMedCentral

57.

Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E (1998) Left ventricular hypertrophy in renal failure. Kidney Int 68:S78-85

Title: Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University
Authors: Nikolaus Marx
Heidi Noels
Joachim Jankowski
Jürgen Floege
Danilo Fliser
Michael Böhm
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue Special Issue 2/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-018-1260-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2018

Biomarker in cardiology

Transcatheter aortic valve implantation in Germany

Current and future aspects of multimodal and fusion imaging in structural and coronary heart disease

Therapeutic options in advanced heart failure

Progress in heart failure treatment in Germany

Genetics of coronary artery disease in the light of genome-wide association studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page